Dr Reddy's PARA IV Pipeline Analysis
Dr Reddys has pipeline of ~20 Para IVs having branded sales of ~$24b. Among its Para IV pipeline the confirmed opportunities (branded sales ~$11.2b) are Exelon, Propecia, Zyprexa (20 mg), Allegra D24, Allegra D12, Actos, Avelox, Antara, and Namenda. Among these products Propecia and Zyprexa are the most lucrative ones. For Para IVs pending outcome we believe the most beneficial could be Fosamax Plus D. Other than this company could be among early entrants in the billion dollar products like Nexium, Lipitor and Geodon. We expect PAT of ~$185m from the Dr. Reddy’s Para IVs which is ~3% of the current market Cap.
COMPANIES MENTIONED
LUPIN, LPC
LUPIN, LPC
More Publications
Para IV Pipeline Analysis of Indian Pharma Companies
US$ 400.00
June 2011
214 pages
AUROBINDO'S, NATCO'S, WOCKHARDT'S PARA IV PIPELINE ANALYSIS
US$ 350.00
June 2011
30 pages
Lupin's PARA IV Pipeline Analysis
US$ 350.00
June 2011
28 pages
RANBAXY'S PARA IV PIPELINE ANALYSIS
US$ 350.00
June 2011
22 pages
Sun Pharma's Para IV Pipeline Analysis
US$ 350.00
June 2011
27 pages
